This article is distributed under the terms of the Creative Commons Attribution Non-Commercial License, which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
Duffy MJ, McGowan PM, Harbeck N, Thomssen C, Schmitt M. uPA and PAI-1 as biomarkers in breast cancer: validated for clinical use in level-ofevidence-1 studies. Breast Cancer Res 2014; 16: 428.DuffyMJMcGowanPMHarbeckNThomssenCSchmittMuPA and PAI-1 as biomarkers in breast cancer: validated for clinical use in level-ofevidence-1 studiesBreast Cancer Res20141642810.1186/s13058-014-0428-4442364325677449Search in Google Scholar
Hayes DF, Bast RC, Desch CE, Fritsche H Jr, Kemeny NE, Jessup JM, et al. Tumor marker utility grading system: a framework to evaluate clinical utility of tumor markers. J Natl Cancer Inst 1996; 88: 1456-66.HayesDFBastRCDeschCEFritscheHJrKemenyNEJessupJMTumor marker utility grading system: a framework to evaluate clinical utility of tumor markersJ Natl Cancer Inst19968814566610.1093/jnci/88.20.14568841020Search in Google Scholar
Jänicke F, Prechtl A, Thomssen C, Harbeck N, Meisner C, Untch M, et al. Randomized adjuvant chemotherapy trial in high-risk, lymph node-negative breast cancer patients identified by urokinase-type plasminogen activator and plasminogen activator inhibitor type 1. J Natl Cancer Inst 2001; 93: 913-20.JänickeFPrechtlAThomssenCHarbeckNMeisnerCUntchMRandomized adjuvant chemotherapy trial in high-risk, lymph node-negative breast cancer patients identified by urokinase-type plasminogen activator and plasminogen activator inhibitor type 1J Natl Cancer Inst2001939132010.1093/jnci/93.12.91311416112Search in Google Scholar
Harbeck N, Schmitt M, Meisner C, Friedel C, Untch M, Schmidt M, et al. Ten-year analysis of the prospective multicentre Chemo-N0 trial validates American Society of Clinical Oncology (ASCO)-recommended biomarkers uPA and PAI-1 for therapy decision making in node-negative breast cancer patients. Eur J Cancer 2013; 49: 1825-35.HarbeckNSchmittMMeisnerCFriedelCUntchMSchmidtMTen-year analysis of the prospective multicentre Chemo-N0 trial validates American Society of Clinical Oncology (ASCO)-recommended biomarkers uPA and PAI-1 for therapy decision making in node-negative breast cancer patientsEur J Cancer20134918253510.1016/j.ejca.2013.01.00723490655Search in Google Scholar
Look MP, van Putten WL, Duffy MJ, Harbeck N, Christensen IJ, Thomssen C, et al. Pooled analysis of prognostic impact of urokinase-type plasminogen activator and its inhibitor PAI-1 in 8377 breast cancer patients. J Natl Cancer Inst 2002; 94: 116-28.LookMPvan PuttenWLDuffyMJHarbeckNChristensenIJThomssenCPooled analysis of prognostic impact of urokinase-type plasminogen activator and its inhibitor PAI-1 in 8377 breast cancer patientsJ Natl Cancer Inst2002941162810.1093/jnci/94.2.11611792750Search in Google Scholar
Hammond ME, Hayes DF, Dowsett M, Allred DC, Hagerty KL, Badve S, et al. American Society of Clinical Oncology/College Of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer. J Clin Oncol 2010; 28: 2784-95.HammondMEHayesDFDowsettMAllredDCHagertyKLBadveSAmerican Society of Clinical Oncology/College Of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancerJ Clin Oncol20102827849510.1200/JCO.2009.25.6529288185520404251Search in Google Scholar
Wolff AC, Hammond ME, Hicks DG, Dowsett M, McShane LM, Allison KH, et al. American Society of Clinical Oncology; College of American Pathologists. Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update. J Clin Oncol 2013; 31: 3997-4013.WolffACHammondMEHicksDGDowsettMMcShaneLMAllisonKHAmerican Society of Clinical Oncology; College of American Pathologists. Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline updateJ Clin Oncol2013313997401310.1200/JCO.2013.50.998424101045Search in Google Scholar
Harbeck N, Dettmar P, Thomssen C, Berger U, Ulm K, Kates R, et al. Riskgroup discrimination in node-negative breast cancer using invasion and proliferation markers: 6-year median follow-up. Br J Cancer 1999; 80: 419-26.HarbeckNDettmarPThomssenCBergerUUlmKKatesRRiskgroup discrimination in node-negative breast cancer using invasion and proliferation markers: 6-year median follow-upBr J Cancer1999804192610.1038/sj.bjc.6690373236231310408848Search in Google Scholar
Harbeck N, Kates RE, Schmitt M. Clinical relevance of invasion factors urokinase-type plasminogen activator and plasminogen activator inhibitor type 1 for individualized therapy decisions in primary breast cancer is greatest when used in combination. J Clin Oncol 2002; 20: 1000-7.HarbeckNKatesRESchmittMClinical relevance of invasion factors urokinase-type plasminogen activator and plasminogen activator inhibitor type 1 for individualized therapy decisions in primary breast cancer is greatest when used in combinationJ Clin Oncol2002201000710.1200/JCO.2002.20.4.100011844823Search in Google Scholar
Foekens JA, Schmitt M, van Putten WL, Peters HA, Bontenbal M, Jänicke F, et al. Prognostic value of urokinase-type plasminogen activator in 671 primary breast cancer patients. Cancer Res 1992; 52: 6101-5.FoekensJASchmittMvan PuttenWLPetersHABontenbalMJänickeFPrognostic value of urokinase-type plasminogen activator in 671 primary breast cancer patientsCancer Res19925261015Search in Google Scholar
Jänicke F, Schmitt M, Pache L, Ulm K, Harbeck N, Höfler H, et al. Urokinase (uPA) and its inhibitor PAI-1 are strong and independent prognostic factors in node-negative breast cancer. Breast Cancer Res Treat 1993; 24: 195-208.JänickeFSchmittMPacheLUlmKHarbeckNHöflerHUrokinase (uPA) and its inhibitor PAI-1 are strong and independent prognostic factors in node-negative breast cancerBreast Cancer Res Treat19932419520810.1007/BF018332608435475Search in Google Scholar
Eppenberger U, Kueng W, Schlaeppi JM, Roesel JL, Benz C, Mueller H, et al. Markers of tumor angiogenesis and proteolysis independently define high- and low-risk subsets of node-negative breast cancer patients. J Clin Oncol 1998; 16: 3129-36.EppenbergerUKuengWSchlaeppiJMRoeselJLBenzCMuellerHMarkers of tumor angiogenesis and proteolysis independently define high- and low-risk subsets of node-negative breast cancer patientsJ Clin Oncol19981631293610.1200/JCO.1998.16.9.31299738585Search in Google Scholar
Peyrat JP, Vanlemmens L, Fournier J, Huet G, Révillion F, Bonneterre J. Prognostic value of p53 and urokinase-type plasminogen activator in nodenegative human breast cancers. Clin Cancer Res 1998; 4: 189-96.PeyratJPVanlemmensLFournierJHuetGRévillionFBonneterreJPrognostic value of p53 and urokinase-type plasminogen activator in nodenegative human breast cancersClin Cancer Res1998418996Search in Google Scholar
Kim SJ, Shiba E, Kobayashi T, Yayoi E, Furukawa J, Takatsuka Y, et al. Prognostic impact of urokinase-type plasminogen activator (PA), PA inhibitor type-1, and tissue-type PA antigen levels in node-negative breast cancer: a prospective study on multicenter basis. Clin Cancer Res 1998; 4: 177-82.KimSJShibaEKobayashiTYayoiEFurukawaJTakatsukaYPrognostic impact of urokinase-type plasminogen activator (PA), PA inhibitor type-1, and tissue-type PA antigen levels in node-negative breast cancer: a prospective study on multicenter basisClin Cancer Res1998417782Search in Google Scholar
Malmström P, Bendahl PO, Boiesen P, Brünner N, Idvall I, Fernö M. S-phase fraction and urokinase plasminogen activator are better markers for dist ant recurrences than Nottingham Prognostic Index and histologic grade in a prospective study of premenopausal lymph node-negative breast cancer. J Clin Oncol 2001; 19: 2010-9.MalmströmPBendahlPOBoiesenPBrünnerNIdvallIFernöMS-phase fraction and urokinase plasminogen activator are better markers for dist ant recurrences than Nottingham Prognostic Index and histologic grade in a prospective study of premenopausal lymph node-negative breast cancerJ Clin Oncol2001192010910.1200/JCO.2001.19.7.201011283134Search in Google Scholar
Meo S, Dittadi R, Peloso L, Gion M. The prognostic value of vascular endothelial growth factor, urokinase plasminogen activator and plasminogen activator inhibitor-1 in node-negative breast cancer. Int J Biol Markers 2004; 19: 282-8.MeoSDittadiRPelosoLGionMThe prognostic value of vascular endothelial growth factor, urokinase plasminogen activator and plasminogen activator inhibitor-1 in node-negative breast cancerInt J Biol Markers200419282810.1177/172460080401900405Search in Google Scholar
De Cremoux P, Grandin L, Diéras V, Savignoni A, Degeorges A, Salmon R, et al. Urokinase-type plasminogen activator and plasminogen-activator-inhibitor type 1 predict metastases in good prognosis breast cancer patients. Anticancer Res 2009; 29: 1475-82.De CremouxPGrandinLDiérasVSavignoniADegeorgesASalmonRUrokinase-type plasminogen activator and plasminogen-activator-inhibitor type 1 predict metastases in good prognosis breast cancer patientsAnticancer Res200929147582Search in Google Scholar
Rabi ZA, Todorović-Raković N, Vujasinović T, Milovanović J, Nikolić-Vukosavljević D. Markers of progression and invasion in short term follow up of untreated breast cancer patients. Cancer Biomark 2015; 15: 745-54.RabiZATodorović-RakovićNVujasinovićTMilovanovićJNikolić-VukosavljevićDMarkers of progression and invasion in short term follow up of untreated breast cancer patientsCancer Biomark2015157455410.3233/CBM-15051626406416Search in Google Scholar
Konecny G, Untch M, Arboleda J, Wilson C, Kahlert S, Boettcher B, et al. Her-2/neu and urokinase-type plasminogen activator and its inhibitor in breast cancer. Clin Cancer Res 2001; 7: 2448-57.KonecnyGUntchMArboledaJWilsonCKahlertSBoettcherBHer-2/neu and urokinase-type plasminogen activator and its inhibitor in breast cancerClin Cancer Res20017244857Search in Google Scholar
Berney CR, Yang J, Fisher RJ, Russell PJ, Crowe PJ. Correlates of urokinasetype plasminogen activator in colorectal cancer: positive relationship with nm23 and c-erbB-2 protein expression. Oncol Res 1998; 10: 47-54.BerneyCRYangJFisherRJRussellPJCrowePJCorrelates of urokinasetype plasminogen activator in colorectal cancer: positive relationship with nm23 and c-erbB-2 protein expressionOncol Res1998104754Search in Google Scholar
Allgayer H, Babic R, Gruetzner KU, Tarabichi A, Schildberg FW, Heiss MM. c-erbB-2 is of independent prognostic relevance in gastric cancer and is associated with the expression of tumor-associated protease systems. J Clin Oncol 2000; 18: 2201-9.AllgayerHBabicRGruetznerKUTarabichiASchildbergFWHeissMMc-erbB-2 is of independent prognostic relevance in gastric cancer and is associated with the expression of tumor-associated protease systemsJ Clin Oncol2000182201910.1200/JCO.2000.18.11.220110829039Search in Google Scholar
Harbeck N, Dettmar P, Thomssen C, Henselmann B, Kuhn W, Ulm K, et al. Prognostic impact of tumor biological factors on survival in node-negative breast cancer. Anticancer Res 1998; 18: 2187-97.HarbeckNDettmarPThomssenCHenselmannBKuhnWUlmKPrognostic impact of tumor biological factors on survival in node-negative breast cancerAnticancer Res199818218797Search in Google Scholar
Bouchet C, Ferrero-Poüs M, Hacène K, Becette V, Spyratos F. Limited prognostic value of c-erbB-2 compared to uPA and PAI-1 in primary breast carcinoma. Int J Biol Markers 2003; 18: 207-17.BouchetCFerrero-PoüsMHacèneKBecetteVSpyratosFLimited prognostic value of c-erbB-2 compared to uPA and PAI-1 in primary breast carcinomaInt J Biol Markers2003182071710.1177/172460080301800309Search in Google Scholar
Buta M, Džodić R, Đurišić I, Marković I, Vujasinović T, Markićević M, et al. Potential clinical relevance of uPA and PAI-1 levels in node-negative, postmenopausal breast cancer patients bearing histological grade II tumors with ER/PR expression, during an early follow-up. Tumour Biol 2015; 36: 8193-200.ButaMDžodićRĐurišićIMarkovićIVujasinovićTMarkićevićMPotential clinical relevance of uPA and PAI-1 levels in node-negative, postmenopausal breast cancer patients bearing histological grade II tumors with ER/PR expression, during an early follow-upTumour Biol201536819320010.1007/s13277-015-3573-125994573Search in Google Scholar
Zemzoum I, Kates RE, Ross JS, Dettmar P, Dutta M, Henrichs C, et al. Invasion factors uPA/PAI-1 and HER2 status provide independent and complementary information on patient outcome in node-negative breast cancer. J Clin Oncol 2003; 21: 1022-8.ZemzoumIKatesRERossJSDettmarPDuttaMHenrichsCInvasion factors uPA/PAI-1 and HER2 status provide independent and complementary information on patient outcome in node-negative breast cancerJ Clin Oncol2003211022810.1200/JCO.2003.04.17012637466Search in Google Scholar
Schmidt M, Lewark B, Kohlschmidt N, Glawatz C, Steiner E, Tanner B, et al. Long-term prognostic significance of HER-2/neu in untreated node-negative breast cancer depends on the method of testing. Breast Cancer Res 2005; 7: R256-66.SchmidtMLewarkBKohlschmidtNGlawatzCSteinerETannerBLong-term prognostic significance of HER-2/neu in untreated node-negative breast cancer depends on the method of testingBreast Cancer Res20057R2566610.1186/bcr991106413915743506Search in Google Scholar
Harbeck N, Alt U, Berger U, Krüger A, Thomssen C, Jänicke F, et al. Prognostic impact of proteolytic factors (urokinase-type plasminogen activator, plasminogen activator inhibitor 1, and cathepsin B, D, and L) in primary breast cancer reflects effects of adjuvant systemic therapy. Clin Cancer Res 2001; 7: 2757-64.HarbeckNAltUBergerUKrügerAThomssenCJänickeFPrognostic impact of proteolytic factors (urokinase-type plasminogen activator, plasminogen activator inhibitor 1, and cathepsin B, D, and L) in primary breast cancer reflects effects of adjuvant systemic therapyClin Cancer Res20017275764Search in Google Scholar
Cufer T, Borstnar S, Vrhovec I. Prognostic and predictive value of the urokinase-type plasminogen activator (uPA) and its inhibitors PAI-1 and PAI-2 in operable breast cancer. Int J Biol Markers 2003; 18: 106-15.CuferTBorstnarSVrhovecIPrognostic and predictive value of the urokinase-type plasminogen activator (uPA) and its inhibitors PAI-1 and PAI-2 in operable breast cancerInt J Biol Markers2003181061510.1177/172460080301800203Search in Google Scholar
